Clinical Trial Update: Phase Ib of L-NMMA and Pembrolizumab [Phase 1]

View source ↗

Summary

This completed Phase 1 trial evaluated the combination of L-NMMA with pembrolizumab across multiple cancers, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dna Repair Deficiency Disorders
• Head and Neck Squamous Cell Carcinoma
• Hodgkin Lymphoma
• Melanoma
• Non-small Cell Lung Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• L-NMMA (NG-monomethyl-L-arginine)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Non-Small Cell Lung Cancer, Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2026-04-09